Ningxia Zhongke Biotechnology Balance Sheet Health
Financial Health criteria checks 2/6
Ningxia Zhongke Biotechnology has a total shareholder equity of CN¥323.9M and total debt of CN¥985.7M, which brings its debt-to-equity ratio to 304.4%. Its total assets and total liabilities are CN¥2.9B and CN¥2.6B respectively.
Key information
304.4%
Debt to equity ratio
CN¥985.73m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥21.59m |
| Equity | CN¥323.87m |
| Total liabilities | CN¥2.61b |
| Total assets | CN¥2.94b |
Financial Position Analysis
Short Term Liabilities: 600165's short term assets (CN¥202.1M) do not cover its short term liabilities (CN¥1.8B).
Long Term Liabilities: 600165's short term assets (CN¥202.1M) do not cover its long term liabilities (CN¥777.9M).
Debt to Equity History and Analysis
Debt Level: 600165's net debt to equity ratio (297.7%) is considered high.
Reducing Debt: 600165's debt to equity ratio has increased from 48.7% to 304.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 600165 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 600165 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 18.3% per year.